Analysts think EXAS stock price could increase by 59%
Apr 03, 2025, 11:25 AM
15.75%
What does EXAS do
EXACT Sciences, headquartered in Madison, Wisconsin, focuses on cancer screening and diagnostics, employing 6,500 people. Its key products include the Cologuard test for colorectal cancer and Oncotype DX tests for breast cancer.
27 analysts think EXAS stock price will increase by 59.44%. The current median analyst target is $71.05 compared to a current stock price of $44.56. The lowest analysts target is $52.52 and the highest analyst target is $90.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
